<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03593317</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL18_0038</org_study_id>
    <nct_id>NCT03593317</nct_id>
  </id_info>
  <brief_title>Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD</brief_title>
  <acronym>BRAVE</acronym>
  <official_title>Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD: a Double-blind Multicentre Prospective Randomized Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arrhythmogenic right ventricular dysplasia (ARVD) is a rare cardiomyopathy characterized by
      the progressive replacement of cardiomyocytes by fatty and fibrous tissue in the right
      ventricle (RV). These infiltrations lead to cardiac electrical instability and ventricular
      arrhythmia.

      Current treatment for ARVD is empirical and essentially based on treatment of arrhythmia.
      Thus, there is no validated treatment that will prevent the deterioration of the RV function
      in patients with ARVD.

      The investigator's hypothesis is that the use of anti-fibrotic medications will prevent or at
      least reduce the deterioration of the RV function. The aim of this project is to evaluate the
      effect of Ramipril, an angiotensin-converting enzyme inhibitor, on ventricular myocardial
      remodeling and on arrhythmia burden in patients with ARVD.

      The trial is a double-blind parallel multicenter prospective randomized phase IV drug study.
      Patients will be randomized in the two groups: ramipril or placebo. 26 centers in France will
      enroll the 120 patients (60 per group). Patients will be followed up every 6 months for 3
      years. A decrease in right and/or left ventricular deterioration and in arrhythmia burden are
      expected in ARVD patients treated with ramipril. This reduction will improve the quality of
      life of patients and will reduce the number of hospitalizations and the risk of terminal
      heart failure.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Right ventricle volume measured by MRI</measure>
    <time_frame>at year 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of ventricular extrasystoles on 24h-Holter ECG</measure>
    <time_frame>at year 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>left ventricle measured by MRI</measure>
    <time_frame>at year 3</time_frame>
    <description>Morphologic criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>left ventricle measured by echocardiography</measure>
    <time_frame>at year 3</time_frame>
    <description>Morphologic criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aneurism measured by MRI</measure>
    <time_frame>at year 3</time_frame>
    <description>Morphologic criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aneurism measured by echocardiography</measure>
    <time_frame>at year 3</time_frame>
    <description>Morphologic criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dyskinesia measured by MRI</measure>
    <time_frame>at year 3</time_frame>
    <description>Morphologic criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dyskinesia measured echocardiography</measure>
    <time_frame>at year 3</time_frame>
    <description>Morphologic criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evolution of QRS width (50mm/s) on ECG</measure>
    <time_frame>at year 3</time_frame>
    <description>Morphologic criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of ventricular extrasystoles on 24h Holter ECG</measure>
    <time_frame>at year 3</time_frame>
    <description>Rhythmic criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sustained ventricular tachycardia on 24h Holter ECG</measure>
    <time_frame>at year 3</time_frame>
    <description>Rhythmic criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evolution of PR interval duration on ECG</measure>
    <time_frame>at 6 month</time_frame>
    <description>Rhythmic criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late potentials measured with high amplification ECG</measure>
    <time_frame>at year 3</time_frame>
    <description>Rhythmic criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of ventricular extrasystoles by stress test</measure>
    <time_frame>at year 3</time_frame>
    <description>Rhythmic criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of functional symptoms by recording adverse events</measure>
    <time_frame>at year 3</time_frame>
    <description>Functional criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospital admissions owing to clinical deterioration</measure>
    <time_frame>at year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of telediastolic right ventricle volume measured by MRI</measure>
    <time_frame>at year 3</time_frame>
    <description>according to the genotype of desmosome genes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arrhythmia burden measured by 24h Holter ECG</measure>
    <time_frame>at year 3</time_frame>
    <description>according to the genotype of desmosome genes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of MMP9 (Matrix metallopeptidase 9)</measure>
    <time_frame>at year 3</time_frame>
    <description>Quantification of fibrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of TIMP1 (Tissue Inhibitory MetalloProtease 1)</measure>
    <time_frame>at year 3</time_frame>
    <description>Quantification of fibrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of TIMP2 (Tissue Inhibitory MetalloProtease 2)</measure>
    <time_frame>at year 3</time_frame>
    <description>Quantification of fibrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of IL6 (Interleukin 6)</measure>
    <time_frame>at year 3</time_frame>
    <description>Quantification of inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of IL8 (Interleukin 8)</measure>
    <time_frame>at year 3</time_frame>
    <description>Quantification of inflammation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Arrhythmogenic Right Ventricular Dysplasia</condition>
  <arm_group>
    <arm_group_label>Ramipril group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>The doses used in the study are the doses used in standard clinical practice. The dose will be adjusted in steps of 2.5 mg every week until the optimal dose. The optimal dose is usually between 5mg to 10mg per day. Ramipril must be taken before, during or after meals; Ramipril will be take once a day at the same time of day. The duration of treatment for each patient is 36 months.</description>
    <arm_group_label>Ramipril group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be take once a day at the same time of day. The duration of treatment for each patient is 36 months.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18years old

          -  Diagnosis of ARVD based on Task Force criteria. Two major criteria: 1 morphologic and
             one rhythmic or 1 major and 2 minor criteria established by the European Society of
             Cardiology/International Society and Federation of Cardiology.

          -  Increased right ventricular volume (&gt; 100ml/m² female; &gt; 110ml/m² male)

          -  Left Ventricular Ejection Fraction &gt;40%

          -  Written informed consent.

        Exclusion Criteria:

          -  Pregnancy.

          -  No health insurance.

          -  MRI contraindication (claustrophobia, implantable defibrillator).

          -  Right heart failure patient (RV volume&gt;150ml)

          -  Ramipril contraindication (hypotension, renal failure).

          -  Normal right ventricular volume

          -  Heart transplantation

          -  Swallowing disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Chevalier, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elodie Morel, PhD</last_name>
    <phone>4 72 35 73 81</phone>
    <phone_ext>+33</phone_ext>
    <email>elodie.morel01@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philippe Chevalier, MD, PhD</last_name>
    <phone>4 72 35 70 27</phone>
    <phone_ext>+33</phone_ext>
    <email>philippe.chevalier@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Cardiologique Louis Pradel</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Philippe Chevalier</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 10, 2018</study_first_submitted>
  <study_first_submitted_qc>July 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2018</study_first_posted>
  <last_update_submitted>December 18, 2019</last_update_submitted>
  <last_update_submitted_qc>December 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Right ventricle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmogenic Right Ventricular Dysplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

